[1] de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013 ;445(1-2):2-10.
[2] Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009, 10(4):321-2.
[3] Baay MF, Kjetland EF, Ndhlovu PD, Deschoolmeester V, Mduluza T, Gomo E, Friis H, Midzi N, Gwanzura L, Mason PR, Vermorken JB, Gundersen SG. Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution. J Med Virol 2004, 73: 481-485.
[4] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127: 2893-2917.
[5] Flores-Pulido JJ, Martínez-Correa M. Cervical cancer and human papillomavirus. A glance from a family medical viewpoint. Rev Med Inst Mex Seguro Soc. 2015, 53 Suppl 2:S162-164.
[6] Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer 2012, 130: 641-652.
[7] Zhao FH, Hu SY, Zhang SW, Chen WQ, Qiao YL. Cervical cancer mortality in 2004–2005 and changes during last 30 years in China. Zhonghua Yu Fang Yi Xue Za Zhi 2010, 44: 408-412
[8] Gu XY, Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen WQ, He J. Incidence and mortality of cervical cancer in China, 2014. Zhonghua Zhong Liu Za Zhi. 2018, 40(4):241-246.
[9] Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev 2010, 12: 1149-1153.
[10] Nakagawa M, Spencer HJ, Coleman HN, Greenfield WW. Distribution of human papillomavirus (HPV) types and anti-HPV T-cell immune responses among different racial/ethnic groups in Central Arkansas. J Ark Med Soc 2013, 109: 160-163.
[11] Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30 (Suppl 5): F12-F23.
[12] Ye J, Cheng X, Chen X, Ye F, Lu W, Xie X. Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol J 2010, 7: 66.
[13] Lou H, Gharzouzi E, Guerra SP, Domgue JF, Sawitzke J, Villagran G, Garland L, Boland JF, Wagner S, Rosas H, Troxler J, McMillen H, Kessing B, Alvirez E, Castillo M, Morales H, Argueta V, Rosingh A, van Aerde-van Nunen FJHB, Lopez G, Pinedo HM, Schiffman M, Dean M, Orozco R. Low-cost HPV testing and the prevalence of cervical infection in asymptomatic populations in Guatemala. BMC Cancer. 2018, 18(1):562.
[14] Sohrabi A, Hajia M. Cervical Cancer and Genital Infections: Assessment of Performance and Validation in Human Papillomavirus Genotyping Assays in Iran, its Neighbouring Countries and Persian Gulf Area. Iran J Pathol. 2017, 12:35-44.
[15] Liu ZH, Lin W, Wang YY, Wu B, Yuan SX, Yao JL, Zhao XS, Chen B, Qiao YL, Zhao FH, Chen W, Hu SY. Risk stratification of type-specific human papillomavirus for cervical precancers: evidence from a cross-sectional study in Shenzhen. Zhonghua Zhong Liu Za Zhi. 2018;40(10):757-763.
[16] Baloch Z, Yuan T, Wang B, Tai W, Feng Y, Liu Y, Li X, Feng Y, Liu L, Zhang AM, Wu X, Xia X. Ethnic and geographic variations in HPV prevalence and genotype distribution in North-Western Yunnan, China. J Med Virol 2016, 88: 532-540.
[17] Baloch Z, Yuan T, Yindi S, Feng Y, Tai W, Liu Y, Liu L, Zhang A, Wang B, Wu X, Xia X. Prevalence of genital human papillomavirus among rural and urban populations in southern Yunnan province, China. Braz J Med Biol Res. 2016, 49(6): e5254.
[18] Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, Huang RD, Sun LX, Meijer CJ, Qiao YL, Franceschi S. Human papillomavirus infection in Shanxi Province, People’s Republic of China: a population-based study. Br J Cancer 2006, 95: 96-101.
[19] Chen X, Wallin KL, Duan M, Gharizadeh B, Zheng B, Qu P. Prevalence and genotype distribution of cervical human papillomavirus (HPV) among women in urban Tianjin, China. J Med Virol. 2015, 87(11):1966-1972..
[20] Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Qiao YL, Franceschi S. Human papillomavirus infection in Shenyang City, People’s Republic of China: A population-based study. Br J Cancer 2006, 95: 1593-1597.
[21] Lin H, Ma YY, Moh JS, Ou YC, Shen SY, Changchien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol 2006, 101: 40-45.
[22] Dillner J, Nygård M, Munk C, Hortlund M, Hansen BT, Lagheden C, Liaw KL, Kjaer SK. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 2018, pii: S0264-410X(18)30626-1.
[23] Shen J, Gao LL, Zhang Y, Han LL, Wang JD. Prevalence of high-risk HPV and its distribution in cervical precancerous lesions among 35-64 years old women who received cervical cancer screening in Beijing. Zhonghua Yu Fang Yi Xue Za Zhi 2018, 52(5):493-497.
[24] Sun LL, Jin Q, Li H, Zhou XR, Song ZQ, Cheng XM, Tao T, Liang B, Xu L, Wang YR, Zhen Y, He JW, Shen K. Population-based study on the prevalence of and risk factors for human papillomavirus infection in Qujing of Yunnan province, Southwest China. Virol J 2012, 9:153.
[25] Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005, 191: 1796-1807.
[26] He L, He J. Distribution of high-risk HPV types among women in Sichuan province, China: a cross-sectional study. BMC Infect Dis. 2019;19(1):390.
[27] Baloch Z, Yue L, Yuan T, Feng Y, Tai W, Liu Y, Wang B, Li X, Liu L, Zhang AM, Wu X, Xia X. Status of human papillomavirus infection in the ethnic population in Yunnan Province, China. Biomed Res Int 2015, 2015: 314815.
[28] Li C,Wu M,Wang J, Zhang S, Zhu L, Pan J, Zhang W. A population based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing, People’s Republic of China. Cancer Epidemiol Biomarkers Prev 2010, 19: 2655-2664.
[29] Jin Q, Shen K, Li H, Zhou XR, Huang HF, Leng JH, Zhang WH, Gong XM, Cheng XM, Suo L, Zhu YC, Lang JH, Lu CM, Wang P, Mo WX. Prevalence of human papillomavirus infection in women in Tibet Autonomous Region of China. Zhonghua Fu Chan Ke Za Zhi 2009, 44: 898-902.
[30] Vargas-Robles D, Magris M, Morales N, de Koning MNC, Rodríguez I, Nieves T, Godoy-Vitorino F, Sánchez GI, Alcaraz LD, Forney LJ, Pérez ME, García-Briceño L, van Doorn LJ, Domínguez-Bello MG.High Rate of Infection by Only Oncogenic Human Papillomavirus in Amerindians. mSphere. 2018, 3(3). pii: e00176-18.
[31] Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M. Cervical HPV infection and neoplasia in a large populationbased prospective study: the Manchester cohort. Br J Cancer 2004, 91: 942-953.
[32] Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, Qiao YL, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Meijer CJ, Muñoz N. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006, 119: 2677-2684.
[33] Preston SM, Darrow WW.Improving Human Papillomavirus-Related Knowledge and Attitudes Among Ethnically Diverse Young Adults. Health Equity. 2019, 3(1):254-263.
[34] Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S; IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366: 991-998.
[35] Yamasaki K, Miura K, Shimada T, Miura S, Abe S, Murakami M, Sameshima T, Fujishita A, Kotera K, Kinoshita A, Yoshiura K, Masuzaki H. Epidemiology of human papillomavirus genotypes in pregnant Japanese women. J Hum Genet 2011, 56: 313-315.
[36] Xiang F, Guan Q, Liu X, Xiao H, Xia Q, Liu X, Sun H, Song X, Zhong Y, Yuan CH, Xiang Y. Distribution characteristics of different human papillomavirus genotypes in women in Wuhan, China. J Clin Lab Anal. 2018, e22581.
[37] Xu H, FH, Gao XH, Hu SY, Chen JF, Liu ZH, Xu XL, Gao LM, Liu QG, Ma L, Liu YJ, Qiao YL. Cost-effectiveness analysis on the once-in-a-lifetime cervical cancer screening program for women living in rural and urban areas of China. Zhonghua Liu Xing Bing Xue Za Zhi 2013, 34: 399-403.
[38] de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7: 453-459.
[39] Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26 (Suppl 10): K1-16.
[40] Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: a review. Virus Res 2002, 89: 229-240.
[41] Li S, Shen H, Li J, Hou X, Zhang K, Li J. Prevalence of the integration status for human papillomavirus 16 in esophageal carcinoma samples. Turk J Gastroenterol. 2018, 29(2):157-163.
[42] Tang SY,Liu ZH,Li L,Cai HL,Wan YP. Awareness and Knowledge about Human Papillomavirus among High School Students in China. J Reprod Med 2014, 59(1-2):44-50.